Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clintrial Refer- a Mobile App To Connect Patients With Local Clinical Trials by Judith Trotman, Xavier Badoux, Admir Huseincehajic, Michele Gambrill, Anais.

Published byAnthony Cannon Modified over 6 years ago

Similar presentations

Presentation on theme: "Clintrial Refer- a Mobile App To Connect Patients With Local Clinical Trials by Judith Trotman, Xavier Badoux, Admir Huseincehajic, Michele Gambrill, Anais."— Presentation transcript:

1 Clintrial Refer- a Mobile App To Connect Patients With Local Clinical Trials
by Judith Trotman, Xavier Badoux, Admir Huseincehajic, Michele Gambrill, Anais LeGall, Michelle Daly, Mark Lacey, Sonia Byrne, Jennifer Aung, Shashi Nair, Penny Mahairas, Cheryl Rine, Karen McCardie, Yvonne Cheung, Molly Forbes, Rebecca Meti, Patricia Plenge, Sharon Clark, Angela Bayley, and Roslyn Ristuccia Blood Volume 122(21): November 15, 2013 ©2013 by American Society of Hematology

2 Xavier Badoux et al. Blood 2013;122:5600
©2013 by American Society of Hematology

Download ppt "Clintrial Refer- a Mobile App To Connect Patients With Local Clinical Trials by Judith Trotman, Xavier Badoux, Admir Huseincehajic, Michele Gambrill, Anais."

Similar presentations

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,
Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner by Angela C. Hirbe, Özge Uluçkan, Elizabeth.

Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner by Angela C. Hirbe, Özge Uluçkan, Elizabeth.
How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.

How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and
Alternate designs for conduct and analysis of phase I cancer trials

Alternate designs for conduct and analysis of phase I cancer trials
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,

A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model by Neil A. Goldenberg, Alex C. Spyropoulos,

Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model by Neil A. Goldenberg, Alex C. Spyropoulos,
by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa
Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.
Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.
Finding a diamond in the (mouse is) rough

Finding a diamond in the (mouse is) rough
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic.
Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Similar presentations

Ads by Google